/ Print /

Policy & Regulation Strategy

Five things to know about Trump’s FDA lead pick GottliebOn March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.
Opinion: More industry-stakeholders play blame game for high drug costsOur policy analyst weighs in on a new drug industry PR campaign that attempts to shift the blame for high drug costs.
Four priorities your health plan must embrace to thrive in the future
Four priorities your health plan must embrace to thrive in the futureHealth plans of the future will focus on consumers: designing products, care and services to support improved health.
Cannabinoid-based drug pipeline grows: 4 ways to prepareNew treatment indications are under investigation for the use of cannabinoid-based drugs. Are you ready?
Opinion: It’s time to rethink how we manage, pay for care for the sickest 10%Health insurance has served different purposes over the years. It may be time to rethink today’s system.
Are high-value health plans the wave of the future?As the destiny of Obamacare takes center stage, two researchers have proposed the next-generation of HSAs-HDHPs, a new way to design health insurance plans that could win bipartisan support.
Opinion: Why Obamacare is so difficult to repealCare for the poor and sick is costly; someone has to pay for it.
Six things to know: How health execs might benefit from Trump’s plansExperts discuss how managed healthcare executives might benefit from the ACA repeal and other healthcare reforms.
Four things to know: Payers’ biggest ACA repeal concernsExperts discuss four of the biggest concerns managed healthcare executives have about repealing the ACA.
Nine things healthcare executives should know about MACRAAlthough CMS released the final rule for MACRA in October, there is still quite a bit of confusion.